Prevalence of psychotic disorders in an urban area of France by Szöke, Andrei et al.
Prevalence of psychotic disorders in an urban area of
France
Andrei Szo¨ke, Gre´goire Baudin, Ghassen Saba, Baptiste Pignon, Jean-Romain
Richard, Marion Leboyer, Franck Schu¨rhoff
To cite this version:
Andrei Szo¨ke, Gre´goire Baudin, Ghassen Saba, Baptiste Pignon, Jean-Romain Richard, et al..
Prevalence of psychotic disorders in an urban area of France. BMC Psychiatry, BioMed Central,
2015, 15 (1), pp.204. <10.1186/s12888-015-0588-5>. <inserm-01264488>
HAL Id: inserm-01264488
http://www.hal.inserm.fr/inserm-01264488
Submitted on 29 Jan 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
RESEARCH ARTICLE Open Access
Prevalence of psychotic disorders in an
urban area of France
Andrei Szöke1,2,3,4,7*, Grégoire Baudin1,2,5, Ghassen Saba1,2, Baptiste Pignon2,4,6, Jean-Romain Richard2,4,
Marion Leboyer1,2,3,4 and Franck Schürhoff1,2,3,4
Abstract
Background: Most data on the prevalence of psychotic disorders is limited to global estimates or restricted to
schizophrenia. Consequently, there is limited information available about the prevalence of psychotic disorders
more widely and outwith age and sex - specific prevalence values. The objective of this study is to provide period
prevalence estimates, detailed by gender and age groups, for treated psychotic disorders in an adult population
(aged 18 years and over) from an urban area in France.
Methods: Prospective reporting of cases treated over an 8-week period complemented by several methods estimating
the number of potentially missed cases, including a leakage study. The study took place in an urban, well
defined catchment area, with a population of 67 430 at risk subjects living in the east of a Paris suburb.
Results: The observed prevalence was of 3.72 per 1000 subjects at risk; after adjustment for potentially lost
cases the estimate was of 4.60 per 1000 subjects at risk. Observed prevalence was higher in men (4.71 per 1000, Relative
Risk = 1.68) and in the 35–45 age-band (6.05 per 1000, Relative Risk = 1.93).
Conclusion: Global prevalence estimates of psychotic disorders in this study are in line with expected values
based on studies conducted in other countries. Careful consideration of the causes of missed cases and gathering of
complementary data are essential and could result in significant changes in prevalence estimates. Detailed estimates
(by age) suggest that treated psychosis might not be a lifelong condition.
Background
Psychotic disorders, characterized by delusions and/or
hallucinations, are the most severe of all mental disor-
ders, representing a major burden for the individual and
the society as well as constituting one of the major
causes of years lived with disability (YLD) in Europe [1].
Prevalence data provide an estimate of the burden of
disease for society and can be used to inform resource
allocation and mental health policy [2, 3].
The prevalence of a disorder is the proportion of people,
in a community, who have the disorder at a given time
(point prevalence), over a given period of time (period
prevalence) including both pre-existing disease and those
who newly develop the disease over this period or who
have ever had the disorder (life-time prevalence) including
people that are in remission.
There are two main methods to identify cases for preva-
lence estimation: clinical studies that enumerate cases in
the health system (including local or national case-
registries) and population surveys. No method is perfect
and each of them has advantages and disadvantages.
Clinical studies are usually less expensive, simpler to im-
plement, and can provide more detailed data [4]. However,
clinical studies typically do not account for cases that are
not in the health system. The probability of being in treat-
ment can depend on several factors not related to the bur-
den of morbidity, such as availability of services, their
location and accessibility and the rate of their utilisation.
The extent of selection bias due to these factors is
probably less important for severe disorders such as schizo-
phrenia [5]. Case-registries are systematic, cumulative data-
bases that improve exhaustivity. They have advantages:
coverage of a defined population, cumulative case registra-
tion over long periods of time and with the capacity to link
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cases with records/information from other databases. How-
ever, they are unable to take into account cases that never
come up for assessment or treatment, as well as providing
less detailed clinical information and have problems which
include diagnostic validity [6].
On the other hand, population surveys can offer infor-
mation on subjects that are not in contact with the health
system. However, they are more difficult to implement
and not free of possible bias, primarily mainly due to non-
responders, which could preferentially be among the sub-
jects with the disorder being surveyed. Furthermore, for
rare mental health disorders, such as schizophrenia, the
validity of the information can be limited [4], due to diffi-
culties in achieving large enough samples. As such, the
different methods of enumerating cases can be seen as of-
fering complementary information on prevalence. Preva-
lence data provide an estimation of the disease burden on
a society and, by assessing needs and service utilisation,
can be used to inform resource allocation and mental
health policy [2, 4].
In 2005, Saha and colleagues conducted the largest
systematic review of the prevalence of schizophrenia
to date. They included data from 188 studies con-
ducted in 46 countries. The median period prevalence
value per 1000 persons was 3.3 (80 % confidence interval
ranging from 1.3 to 8.2 per 1000). However, questions as
to the generalizability of this data emerge, given that most
of these observations come from a very small number of
countries. Of the 132 core studies identified by Saha and
colleagues, more than half were conducted in only 4
countries (United States, United Kingdom, India and
Canada). A similar question as to the generalizability also
occurs in data from Europe, where more than 25 % of the
studies came from the United Kingdom, with 50 % coming
from only three countries (United Kingdom, Denmark and
Germany) [7]. Although the study by Saha and colleagues
was a thorough review, some comparisons of interest, be-
tween specific populations, are not available due to the lack
of original data. For example, there are no prevalence fig-
ures according to age categories, even although such data
combined with incidence data could add to our under-
standing of the outcome (e.g. mean duration of the dis-
order, remission rates) [8].
Furthermore, data from prevalence studies which looked
at psychotic disorders more widely, and not limited to
schizophrenia alone, are very scarce [9–11]. Prevalence
figures for psychotic disorders are variable (ranging from
0.7 to 0.9 % in the cited studies), as is the proportion of
cases diagnosed with schizophrenia (ranging from 0.3 to
0.9 %), mainly due to variations in the definition of
"psychotic disorders".
To our knowledge, there are only a few studies in
France that have investigated the prevalence of psychotic
disorders [12–16]. Some of these studies were in specific
populations (e.g. Falissard et al. studied a population
of male inmates, finding 3.8 % to have psychotic dis-
orders [16]) or in particular settings (e.g. Jay et al. found
very high prevalence rates, 1.49 %, in the Réunion Island -
a French overseas region in the Indian Ocean [14]). How-
ever, given the specificities of these populations, the figures
are not representative of prevalence of psychoses in the
general French population. In the general French popu-
lation, there have been 3 studies to date. Brunetti and
colleagues investigated the prevalence of mental disorders
in a rural town of around 800 inhabitants in 1975. The
prevalence of psychotic disorders (period-prevalence: one
year) was estimated at between 1 and 2 % of the population
but, given the size of the at risk population, it is difficult to
generalize from these findings [12]. According to the study
by Sadoun and colleagues, the point prevalence of hospital-
ized patients in France was of 0.61 to 0.79 per 1000 for
schizophrenia and 0.88 to 1.19 %, when other psychotic
disorders were included [13]. More recently, the French
Mental Health in General Population (MHGP) survey,
conducted by the World Health Organization Collaborat-
ing Centre (WHO-CC), between 1999 and 2003, included
more than 37000 participants, that were representative of
the French population. Subjects were interviewed using the
Mini International Neuropsychiatric Interview (MINI) [17]
in 47 sites across France, with a life-time psychotic disorder
being diagnosed in 2.7 % of the sample (2 % recurrent
psychotic disorders and 0.7 % single psychotic episodes)
[15, 18]. As such, data on psychosis prevalence is very lim-
ited in France, with no recent estimates and large differ-
ences in prevalence from the limited previous studies.
In order to obtain prevalence data on psychosis in France,
we conducted a study estimating the period-prevalence of
treated psychosis in an urban area of France, detailed by
gender and age-bands. Special attention was given to the
precision of the estimates by limiting the number of un-
identified cases and by identifying and correcting all pos-
sible sources of lost cases.
Methods
Catchment area
The study took place in the biggest town of the eastern
suburb of Paris, Créteil (Val de Marne county). The popu-
lation of this town, according to the most recent census
(2011), is of 90 528 (67 430 aged 18 years and over).
Créteil is a densely populated area with 7839.9 inhabi-
tants per square kilometre (versus 990.5 in Ile-de France
region, and 117.0 in the whole of mainland France),
with an ethnically diverse population (migrants repre-
sent 23.48 % of the population compared to 18.16 %
for the whole Region and 8.84 % for mainland France) and
a high unemployment rate: 14.5 % (versus 8.6 %, and 9.4 %
respectively) [19].
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In France, most of the patients diagnosed with severe
psychiatric disorders are treated by psychiatrists within
public practice. A minority are treated by psychiatrists in
private practice and by general practitioners (GP). The
public sector is organized in catchment areas ("secteurs
psychiatriques") that cover well-defined areas of 60000
to 80000 inhabitants. Each of these catchment areas has
inpatient and outpatient settings. For example, the Cre-
teil psychiatric "secteur" has 6 inpatient units and several
outpatient units (for consultations, day care centre, cog-
nitive remediation, etc.).
Participants
We compiled a list of all the practitioners (psychiatrists
and GP) who worked in Creteil and potentially followed
psychotic patients, using several sources (administrative
sources, Yellow Pages, internet search, etc.). We tried to
contact each of these physicians by phone, mail and fi-
nally, when needed, met with them at their office.
When contact was established, the study rationale and
methodology were explained to each practitioner who
was asked to participate. When the physician declined, a
request was made to give an estimation of the mean
number of adult patients with psychotic disorders for
which they prescribed an antipsychotic treatment, over
an 8-week period. There were two reasons for asking for
this estimation. The first was to be able to compare - in
terms of the (expected) number of treated psychotic
subjects - the practitioners that participated in the whole
study with those who did not. Secondly, these numbers
were used to estimate the number of patients treated by
the practitioners that did not participate in the whole
study (for details see below, in additional data used to
estimate missed cases).
Data collection
Data collection began on March 6th and ended on April
30th 2014 (total duration 8 weeks). During this 8-week
period, all participating practitioners prospectively re-
ported the patients they had seen and who met the fol-
lowing inclusion criteria: 18 years old and over, meeting
a diagnosis of psychotic disorder according DSM-IV-TR
(i.e. codes 295.xx, 297.x, 298.x) [20] and receiving an
antipsychotic treatment prescribed during the consult-
ation. The last criterion (prescription of an antipsychotic
during the consultation) was added for two reasons. Firstly,
to avoid including subjects currently in remission. Sec-
ondly, to avoid counting the same subject more than once,
given that subjects were in contact with several physicians
during this study period (e.g. a psychiatrist prescribing the
psychopharmacological treatment, another psychiatrist
supervising psychotherapy at the day-care centre and their
GP managing care for medical/somatic problems).
The forms used to report the cases comprised inclusion
(see above) and exclusion criteria (e.g. symptoms caused
by the effects of a substance, a general medical condition,
or a mood disorder), clinical (e.g. positive and negative
symptoms, age of onset) and socio-demographical data
(e.g. age, sex, month, year and country of birth, an area
code for the address). The forms were anonymous, con-
taining no personal details, such as name, address, which
could lead to the identification of a subject. The private
practice practitioners received the equivalent of a consult-
ation fee for each case reported.
During the survey period, weekly contact was made with
the psychiatrists in the public sector and bi-monthly with
those in private practice in order to remind them about the
study, thereby reducing the risk of errors and missing data.
Additional data used to estimate missed cases
Not all cases could be identified. Before study onset, the
possible reasons for missing cases were analysed. Based
on this analysis, we designed the study in order to gather
the additional information needed to assess the number
of missed cases.
Firstly, for cases seen by their physicians at intervals lon-
ger than 8 weeks, the study period was too short for their
inclusion. Among these subjects, only a fraction, in inverse
proportion with the interval between two appointments,
was reported. In order to calculate the number of subjects
lost for this reason, information was collected about the
interval length between two appointments with their phys-
ician. When this interval was larger than the period of the
study, we counted each case reported not as one but as the
number of weeks between appointments divided by 8 (the
duration, in weeks, of the study). For example: of the sub-
jects seen by their prescribing physicians every 12 weeks, it
was expected that only 2/3 would be reported, given that
the study duration was only 2/3 of the interval between ap-
pointments. To account for the 1/3 of subjects not re-
ported in this scenario, the number of subjects seen at
12 week intervals was multiplied by 12/8.
A second cause for missing cases was due to private
practice physicians not agreeing to participate in the
whole study. To account for this source of lost cases,
we calculated several indexes, based on the data from
private practice physicians with those that participated
in the whole study (GPs and psychiatrists). The first index
reflected the proportion of cases actually reported com-
pared with the cases expected before the study (based on
the physician’s own estimate); the other two indexes were
the mean number of cases reported by a GP or by a psych-
iatrist. The first index was used for physicians who had
given an estimation of the number of cases (before the
study) and the two other indexes were for the physicians
for whom this prior estimation was not available.
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A third possible cause for missing cases is represented
by errors in case reporting, i.e. incomplete reporting by
the physicians that participated in the study. To assess
the number of subjects missed for this reason, we con-
ducted a leakage study. For feasibility reasons, the study
was limited to the outpatient clinic - the main provider
of cases. Six months after the study took place, each of the
psychiatrists working at the outpatient clinic received a list
with the names of all the patients they saw in the period of
the study. The psychiatrists were instructed to indicate the
patients that had a diagnosis of psychotic disorder and,
when in doubt (e.g. between a diagnosis of bipolar disorder
with psychotic symptoms and a schizo-affective disorder),
to consult the case file.
Finally, we estimated that some of the subjects diagnosed
with psychosis were treated outside the city of Créteil,
thereby escaping reporting procedures. There was no
means to exactly assess the number of subjects lost for
this reason. However, the figures for the patients that lived
outside Créteil and were treated in Créteil were available.
Given that Créteil is well equipped for treating psychotic
patients, it was thought reasonable to assume that the
number of subjects treated outside Créteil will be (as a
maximum estimation) equivalent of the number of sub-
jects from outside Créteil treated in Créteil.
Prevalence calculation
For each of the prevalence estimates reported, the numer-
ator was the number of cases counted and/or estimated
and the denominator the total adult population of the
catchment area. All prevalence data are reported per 1000
at risk people and with 95 % confidence intervals (CI).
Data is also provided for the prevalence in subgroups de-
fined by gender and different age-bands. Finally, the preva-
lence based on shorter periods of time (1 to 7 weeks) was
also calculated, in order to estimate the minimum period
needed for a reliable prevalence estimation. To this end,
the number of subjects missed because the time period
was too short was estimated, using the method described
previously (Methods, Additional data used to estimate
missed cases, second paragraph), with these then added to
the number of subjects actually reported. All denominator
data were from the last available census in 2011 [19].
Ethical approval
The relevant Regional Ethical Committee (Comité de Pro-
tection des Personnes – CPP Ile de France VI) examined
and approved the study protocol (project number 2011-
A01209-32) in accordance with the Helsinki Declaration.
Written consent was not requested because the Ethical
Committee agreed that, for ethical reasons, it was im-
portant to preserve anonymity of the subjects. Thus, all
data sent to the researchers by the treating psychiatrists
were anonymous and patients were not in contact with
the research team.
Results
Participants
All 27 psychiatrists belonging to the public sector partici-
pated in the study. Among the private practice psychia-
trists, one could not be contacted, 3 only estimated the
number of patients treated for psychosis and one partici-
pated in the whole study. For GPs, one could not be
reached, 16 refused to participate, 17 provided only an es-
timation of the number of cases and 28 participated in the
whole study (for details see Fig. 1).
First part of the study - estimation of number of cases
before the inclusion period
Before the beginning of the inclusion period, forty-four
private practice practitioners (among them 3 psychiatrists)
provided an estimation of the number of patients that met
the inclusion criteria. The total number of expected
cases over a two-month period for these practitioners
was of 71. The mean number per practitioner was 1.6
(95 % CI 0.81-2.42) and the median number 0.0. Among
these practitioners, 28 also participated in the second part
of the study. For these practitioners, the mean number of
cases anticipated was 2.0 (95 % CI 0.84 - 3.16) and the me-
dian 1.0. This was not significantly different from the
number of cases expected by the non-participating physi-
cians (mean = 0.94, 95 % CI 0.14-1.74).
Number of cases reported
We received a total of 292 forms. Six of them were dupli-
cates (same age, gender, area code, etc.); and 35 were from
subjects outside Créteil. Most of them (229; 78.4 %) came
from the outpatient clinic (for details see Fig. 2). The 28
practitioners who estimated the number of subjects seen
in their practice sent back 5 forms. The leakage study
identified 8 more subjects having the inclusion criteria
and living in Créteil (i.e. 3.5 % of the cases initially re-
ported) and 5 subjects living outside Créteil.
Prevalence calculations
Prevalence based on cases reported
Based on the reported cases and after eliminating the du-
plicates, the global prevalence was 3.72 per 1000. The
prevalence was higher in men (relative risk (RR) = 1.68)
and in the 35–44 years age-band (RR compared with all
other age-bands = 1.93) and lower in the extreme age
bands, i.e. 18–24 (RR = 0.31) and 65 and older (RR = 0.31)
(for details, see Table 1 and Fig. 3).
Estimate of the prevalence of cases treated in Creteil
Only 10 subjects were seen at intervals longer than
8 weeks (mean interval for these subjects = 10.65 weeks).
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This gives an estimate of 3.31 for subjects lost for
this reason.
For private practice practitioners who participated in
the whole study, the number of subjects actually reported
(N = 5) divided by the number expected (N = 56) was of
0.09. The practitioners who participated only in the first
step of the study estimated the number of subjects that
they treated for psychosis to be 15. As such, the number
of subjects lost due to these practitioners not participating
in the whole study was estimated at 1.35. The mean num-
ber of subjects reported by the GPs participating in the
whole study was 0.18. As such, it was estimated that the
number of subjects for the 17 GPs not participating in the
study to be 3.06. For the psychiatrist that did not partici-
pate in the study, we estimated the number of patients
based on the number of patients (without duplicates) re-
ported by the private psychiatrists that did participate in
the whole study, i.e. 7.
Adding all these numbers, the number of forms that
we expected to receive if the study continued for a lon-
ger period of time and if all practitioners had agreed to
participate, was 265.69.
Finally, the leakage study revealed that the proportion
of cases not reported was 3.49 %. When the same pro-
portion was added to the previous estimate, we obtained
a total number of cases of 274.96 and a prevalence of
4.08 per 1000 (95 % CI 2.30-5.85).
Estimate of the prevalence of treated psychosis among the
population of Creteil (including cases treated outside
Créteil)
This estimate is based on the number of subjects with
psychosis from Créteil and treated in or outside Créteil.
The later number was estimated to be equivalent to the
number of patients living outside Créteil, but treated in
Creteil, i.e. 35. (30 cases living outside Créteil identified
Fig. 1 Practitioners present in the catchment area and their participation in the study
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during the data collection plus 5 cases identified during
the leakage study). As such, the estimate of the total
prevalence of treated psychosis in Creteil is 4.60 per
1000 (95 % CI 2.71-6.48) (see Fig. 4 for more details).
Estimation of the raw prevalence at shorter intervals
Figure 5 shows the curve of the prevalence estimated
weekly, based on reported cases. For the general estimate
of prevalence, a 5 week period seems appropriate. A 6 week
period seems more appropriate, if more details are re-
quired, such as prevalence broken down by gender and
age bands (further details available from the authors
on request).
Discussion
In this study, we report data on period prevalence
(8 weeks) of treated psychotic disorders in an urban area
in France. After adjustment for potential sources of lost
cases, the prevalence of treated psychosis was estimated
to be 4.60 per 1000. Most of the cases were outpatients
(79.79 %) that were treated by psychiatrists (98.29 %) in
the public sector (95.55 %).
Taking into account the limitations of the study in
regard to duration (i.e. adjusting for the 8 weeks of the
study period), location (adjusting for patients receiving
their treatment outside Créteil), number of participating
practitioners or the inherent imperfect reporting of cases
(leakage study), the estimated prevalence (3.72 per 1000)
increased by more than 20 %. In a systematic review,
Goldner and colleagues found a period prevalence for
schizophrenia and related disorders of 6.0 per 1000 (95 %
CI 3.8-9.1). Our figures are in the lower half of this confi-
dence intervals, which may be due to the shorter study
period (8 weeks vs. 1 year) and/or to the inclusion of only
treated cases in the study reported here [2].
An interesting finding is indicated by the shape of the
graph of prevalence by age-bands. Based on the assumption
of lifetime disorders, it was expected that the prevalence
would be larger in later age bands, with the possible excep-
tion of the last age band when, due to an excess mortality
in patients with psychosis and small incidence numbers, a
slower decline in prevalence would have been expected. In-
stead, we observed the highest prevalence of psychosis in
the 35–45 year age band. The lower prevalence in subse-
quent age bands could be due to excess mortality in psych-
otic patients, or to secular trends for prevalence (increases
in incidence/prevalence in more recent years). However,
given the amplitude of this decline (almost 40 % between
the 35–45 and the 55–65 age bands), it seems unlikely that
such explanations could completely account for the ob-
served trend, instead suggesting that psychosis, once diag-
nosed, is not a life-time treated disorder.
Incidence rates from the same area are of 0.22 per
1000 subjects*year [21], therefore suggesting a mean
time of 15 to 20 years of treated psychosis. This seems to
be consistent with epidemiological data on schizophrenia
Table 1 Raw prevalence rates by sex and age-bands
Age Bands F (95 % CI) M (95 % CI) Total (95 % CI)
18-24 1.01 (0.13-1.90) 1.57 (0.41-2.73) 1.28 (0.55-2.00)
25-34 2.27 (1.19-3.35) 6.08 (4.18-7.98) 4.03 (2.98-5.08)
35-44 3.80 (2.28-5.31) 8.41 (6.11-10.71) 6.05 (4.69-7.42)
45-54 4.92 (3.22-6.62) 5.08 (3.20-6.95) 4.99 (3.73-6.25)
55-64 3.60 (1.94-5.26) 3.77 (1.98-5.55) 3.68 (2.46-4.89)
65+ 1.34 (0.41-2.27) 1.18 (0.15-2.22) 1.27 (0.58-1.97)
Total 2.87 (2.35-3.39) 4.71 (3.95-5.47) 3.72 (3.26-4.18)
Fig. 2 Source of the reported cases
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summarized by Saha and colleagues for the prevalence [7]
and McGrath and colleagues for incidence (0.15 per 1000
population*year median incidence for schizophrenia),
as well as being consistent with studies [22] that re-
ported both incidence and prevalence data (summa-
rized by Saha et al. [8]), suggesting the same (mean)
interval of follow-up.
Various reasons for this could be suggested: a mixture
of short lived disorders and chronic, life-long disorders,
chronic patients moving preferentially out of the area
(for example to specialized care facilities), milder clinical
forms that are no longer treated, or complete recovery.
Based on longitudinal and long-term follow-up stud-
ies, the annual rate of recovery was estimated by Saha
and colleagues to be 1.37 % [8] suggesting that, although
recovery could explain part of the observed data, it is
probable that it is not the sole explanation. Data from a
more recent meta-analysis of studies on recovery from
schizophrenia and related disorders [23], found a similar
annual recovery rates (1.4 %). However, this study also
suggested that this rate diminishes with the duration of
the disorder [23]. At a constant 1.4 % annual recovery
rate (and without any new cases), the number of subjects
not recovered after 20 years will be around 75 % of the
initial number. We found a significantly larger difference
(40 %) between the third (35–44) and fifth (55–65) age-
bands suggesting that, although recovery could explain a
significant part of the observed data, it is unlikely that it
is the sole explanation. Finding the explanation for this
observation deserves further studies, especially, longitu-
dinally derived data.
As mentioned in the introduction, there are very few
studies on the prevalence of psychotic disorders in France.
The most recent data are from the French Mental Health
in General Population (MHGP). The figures for psychotic
disorders in this study were 2.7 % comprised of 0.7 % sin-
gle psychotic episodes and 2 % recurrent psychotic disor-
ders [15]. Our figures are smaller. Part of the difference
could be due to the MHGP study reporting lifetime preva-
lence, whereas we reported period prevalence. Another
important difference is that we reported treated psychosis
and they reported all cases, treated or not. Finally, the dif-
ference may be due to some of the subjects in the MHGP
study not having been diagnosed with a psychotic disorder
according to DSM criteria, given the lack of duration and/
or impairment criteria in that study. Although the MINI
showed excellent psychometric qualities in a validation
study conducted in a sample comprised of mainly psychi-
atric patients [17], its diagnostic accuracy, especially speci-
ficity, in the general population has, to our knowledge, not
been assessed.
There are several limitations in our study that have to be
acknowledged. Some of the physicians did not participate
in the study. Although we tried to estimate the number of
cases missed for this reason, there are uncertainties about
the exact number of cases. We were surprised by the differ-
ence between the number of cases anticipated by the prac-
titioners and the actual number of cases reported. In
retrospect, one possible explanation is that they included in
their estimation, those patients suffering from psychosis
but for whom antipsychotic treatment was being prescribed
by another physician. It is of note that the two methods of
estimating the number of cases lost due to the GP not par-
ticipating in the whole study (i.e. based on the mean num-
ber of subjects reported by participating GP or based on
the number of subjects anticipated) lead to similar results.
Fig. 3 Raw prevalence (per 1000) by sex and age-bands
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However, not taking into account the number of cases an-
ticipated by the psychiatrists that participated only in the
first step (and consider that they had the same number of
patients as the only private practice psychiatrist that did
participate) would have resulted, in our view, in an over-
estimation. Using this method, the number estimated
would have been of 21 in considerable contrast to their es-
timation of no subject for which they prescribed anti-
psychotic treatment (in their practice they mostly provided
psychotherapy).
Another limitation of the study was that there was no
information from the non-participating physicians and
therefore, we cannot be sure that data from the partici-
pating practitioners accurately represent all cases. How-
ever, more than 80 % of the physicians from the area
participated in at least to the first part of the study. The
physicians that did not participate were, for the most
part, GPs, which was the category of physicians that re-
ported the smallest number of cases. As such, the num-
ber of cases lost for this reason is probably small.
In order to estimate the number of cases lost because er-
rors in reporting, a leakage study was carried out. However,
this study was limited to psychiatrists from the outpatient
clinic and it is uncertain that extending the findings from
Fig. 4 Estimation of the number of cases and prevalence of treated psychosis in Créteil
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the leakage study to all cases would have been appropriate.
Nevertheless, the leakage study covered a large majority of
reported cases (almost 80 %), indicating that even if the
leakage study results for the remaining physicians had been
different, it is probable that the impact on the overall esti-
mation of cases would have been limited.
We had no means to exactly assess the number of sub-
jects living in the area but treated outside Créteil. Créteil
is in close proximity to other urban areas (including Paris),
but is also well equipped for treating patients with psych-
otic disorders. As such, although it is probable that there
is a significant number of subjects that are treated outside
their home town, it is also probable that for Créteil this
number does not exceed the number of patients treated
here but living outside Créteil.
Another limitation of our study is that we did not rec-
ord specific diagnoses. This limits our capacity to com-
pare our results with those in the literature, as most
previous studies reported data only for schizophrenia.
Our method of identifying cases relied on the presence
of characteristic symptoms, which we thought would be
more reliable and comparable across physicians than
specific diagnoses, especially for cases identified by GPs.
One important point to note is the reporting here of the
prevalence of treated psychosis which is, by definition,
smaller that the prevalence of psychosis as a whole. The
number of untreated cases cannot be estimated from this
study. We also made the choice to limit our study to
psychotic disorders as defined by DSM-IV-TR, also called
non-affective psychoses. As a consequence, our findings
do not apply to all disorders with psychotic features, such
as mood disorders with psychotic features (sometimes re-
ferred as "affective psychoses").
Finally, our study took place in a highly urbanized site. It
is not clear if prevalence of psychotic disorders is influ-
enced by urbanization. Although the review by Saha and
colleagues did not find significant differences in prevalence
according to the degree of urbanisation, this contrasts with
consistent data showing significantly higher incidence of
psychotic disorders in urban areas [7, 24, 25]. Therefore, at
this point, our results cannot be generalized to the whole
French population, especially to more rural sites.
There are several potential implications of our results.
Firstly, they underscore the need to reinforce mental health
services that aim to provide adequate and specific care to
young patients. Secondly, they suggest that more research
is needed to understand the sizable difference in prevalence
between subjects in their 40s and subjects in the 55–64
age-band. It is essential that future investigations should
explore the outcome, and the need for psychiatric care, of
patients that are no longer in contact with mental health
services. This may require a raising of the awareness of this
phenomenon and is likely to necessitate a better collabor-
ation between psychiatrists and GPs.
Conclusions
The estimates in our study are in line with expected
numbers that are based on studies conducted in other
countries. In our study, careful consideration of causes
of missed cases and gathering of complementary data
(including a leakage study) aimed at estimating the num-
ber of lost cases, resulted in a significant increase in the
estimated prevalence (more than 20 %). This indicates
that careful consideration of methodological limitations,
prior to study commencement, is essential in order to
obtain valid prevalence estimates.
An interesting finding, deserving further investigations,
is the marked differences between age specific prevalence
rates, with surprisingly relatively low figures in the 55–64
age-band, a finding that is more pronounced in men. Un-
derstanding the origin of the difference between preva-
lence in the 35–44 and 55–64 age-bands may contribute
to the provision of new public health measures that aim to
reduce mortality in this population, as well as improving
Fig. 5 Raw prevalence estimated weekly
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the identification and treatment of patients that are still
symptomatic but no longer in treatment.
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